Lipid-coated silica nanoparticles targeted with RGD-peptides represent a promising new platform for multimodality contrast agents.
No takes yet. Share an insight, caveat, or question.
Huber et al. (1978) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: